DSRLF Live signaler | Maksimer profitt med Getagraph.com

Live Chart Being Loaded With Signals

Commentary (13 mai 2024 @ 19:35):

Stats
Dagens volum	100.00
Gjennomsnittsvolum	3.00
Markedsverdi	5.82B
EPS	$0 ( 2024-05-15 )
Neste inntjeningsdato	( $0 ) 2024-07-29
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	34.17
ATR14	$0 (0.00%)

DiaSorin S.p.A. Korrelasjon

10 Mest positive korrelasjoner

10 Mest negative korrelasjoner

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

DiaSorin S.p.A. Økonomi

Annual	2023
Omsetning:	$1.27B
Bruttogevinst:	$738.49M (58.27 %)
EPS:	$3.16

FY	2023
Omsetning:	$1.27B
Bruttogevinst:	$738.49M (58.27 %)
EPS:	$3.16

FY	2022
Omsetning:	$1.46B
Bruttogevinst:	$884.57M (60.72 %)
EPS:	$4.46

Financial Reports:

No articles found.

DiaSorin S.p.A. Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

DiaSorin S.p.A.

DiaSorin S.p.A. develops, manufactures, and distributes immunodiagnostics and molecular diagnostics testing kits in Europe, Africa, North America, Central and South America, the Asia Pacific, and China. The company provides various immunodiagnostic LIAISON platforms, including LIAISON XS, LIAISON XL, and LIAISON XL LAS; and molecular diagnostics platform comprising of LIAISON MDX for use in the amplification of nucleic acids to diagnose viral infections through the identification of virus in patient's biological sample. It has partnership agreements with QIAGEN for diagnostic solution for Latent Tuberculosis detection; TTP for the development of molecular Point-of-Care solution; and MeMed for the launch of a test differentiating between viral and bacterial infections. The company was founded in 1968 and is headquartered in Saluggia, Italy.